-- Shanghai Henlius Biotech (HKG:2696) said the first subject has been dosed in a Phase 1 clinical study of HLX319 in the Chinese Mainland, according to a Friday Hong Kong bourse filing.
The drug is intended to treat early-stage or locally advanced and metastatic breast cancer.